Recently, in July 2018, Dr. Bennett published a paper about Fluoroquinolone Associated Suicide to the European Journal of Internal Medicine with the assistance of the floxed community.
Tagged: Community News
In an astonishing statement from the FDA, they acknowledged that since “Psychiatric Effects” will specifically be identified within the “Central Nervous System Effects” subheading, psychiatric adverse events are automatically assumed to be part of the existing Black Box warning.
Adverse events added by the FDA are some of those requested by Dr. Bennett previously.
It is promising that such a prestigious journal covered the controversy of the FQ’s.
To those who are new to my plight or are unfamiliar with my personal situation, my life is delineated with a clear demarcation line. The life before taking Levaquin, a fluoroquinolone (FQ) antibiotic, and my life after. My healthy life before and my not so healthy life after. It is my story, my quin story, my life after Levaquin; Extremely healthy in one season, and a struggle with health the next.
On Thursday May 12, 2016 the FDA contacted those who have been pursuing label changes for the Fluoroquinolones and issued a public statement that the FDA is requiring label changes for antibacterial drugs called fluoroquinolones
Dr. Charles Bennett has been able to successfully publish a paper titled “Fluoroquinolone-Related Neuropsychiatric and Mitochondrial Toxicity: a collaborative investigation by scientists and members of a social network.”